De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Enanta Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Enanta Pharmaceuticals' is Jay Luly, benoemd in Jul2003, heeft een ambtstermijn van 21.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.86M, bestaande uit 9.6% salaris en 90.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.51% van de aandelen van het bedrijf, ter waarde $ 7.71M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 7.9 jaar.
Belangrijke informatie
Jay Luly
Algemeen directeur
US$7.9m
Totale compensatie
| Percentage CEO-salaris | 9.6% |
| Dienstverband CEO | 21.3yrs |
| Eigendom CEO | 3.5% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.9yrs |
Recente managementupdates
Recent updates
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$132m |
| Dec 31 2023 | n/a | n/a | -US$138m |
| Sep 30 2023 | US$8m | US$755k | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$125m |
| Dec 31 2022 | n/a | n/a | -US$121m |
| Sep 30 2022 | US$7m | US$725k | -US$122m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$101m |
| Sep 30 2021 | US$5m | US$693k | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | n/a | n/a | -US$58m |
| Sep 30 2020 | US$5m | US$667k | -US$36m |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | US$24m |
| Dec 31 2019 | n/a | n/a | US$34m |
| Sep 30 2019 | US$4m | US$642k | US$46m |
| Jun 30 2019 | n/a | n/a | US$65m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | n/a | n/a | US$86m |
| Sep 30 2018 | US$4m | US$611k | US$72m |
Compensatie versus markt: De totale vergoeding ($USD 7.86M ) Jay } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).
Compensatie versus inkomsten: De vergoeding van Jay is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jay Luly (68 yo)
21.3yrs
Tenure
US$7,856,698
Compensatie
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 21.3yrs | US$7.86m | 3.51% $ 8.1m | |
| Chief Financial & Administrative Officer | 21.1yrs | US$2.85m | 0.35% $ 818.8k | |
| Senior VP of Research & Development and Chief Scientific Officer | 24.9yrs | US$2.97m | 1.66% $ 3.9m | |
| Consultant | less than a year | US$2.86m | 0.43% $ 990.8k | |
| Chief Business Officer | 3.8yrs | US$2.58m | 0.10% $ 238.6k | |
| Senior Director of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Product Strategy Officer | 3.8yrs | US$2.10m | 0.071% $ 164.8k | |
| Senior VP & Chief Medical Officer | 2.2yrs | US$4.84m | 0.017% $ 38.7k |
3.8yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ENTA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 21.3yrs | US$7.86m | 3.51% $ 8.1m | |
| Independent Director | 4.3yrs | US$331.41k | 0% $ 0 | |
| Independent Non-Executive Chairman | 10.9yrs | US$353.91k | 0% $ 0 | |
| Independent Director | 13.3yrs | US$333.91k | 0.027% $ 63.4k | |
| Independent Director | 7.1yrs | US$326.41k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$318.91k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$321.41k | 0% $ 0 |
7.9yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ENTA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).